Get in-depth coverage of current and future trends in technology, and how they are shaping business, entertainment, communications, science, politics, and society.
…
continue reading
A tartalmat a Audioboom and RCGP eLearning Podcast biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Audioboom and RCGP eLearning Podcast vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Player FM - Podcast alkalmazás
Lépjen offline állapotba az Player FM alkalmazással!
Lépjen offline állapotba az Player FM alkalmazással!
Respiratory syncytial virus (RSV)
MP3•Epizód kép
Manage episode 436655401 series 2631159
A tartalmat a Audioboom and RCGP eLearning Podcast biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Audioboom and RCGP eLearning Podcast vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Sponsored by Pfizer Limited. Pfizer has had no involvement in the editorial component of this educational material. Editorial and content decisions were made solely by the RCGP.
Respiratory syncytial virus (RSV) is an RNA virus which causes respiratory infections; the most significant clinical effects are in infants and people who are elderly and have chronic medical conditions or immunosuppression. In this podcast, Professor Simon de Lusignan from the RCGP’s Research and Surveillance Centre discusses the new RSV vaccination programme, which offers a one-off vaccine to everyone at the age of 75, with an initial catch-up programme between the ages of 75 and 80. He also touches on monoclonal antibodies and antivirals, which are given in secondary care to children who are at high risk of serious complications if they contract RSV.
Respiratory syncytial virus (RSV) is an RNA virus which causes respiratory infections; the most significant clinical effects are in infants and people who are elderly and have chronic medical conditions or immunosuppression. In this podcast, Professor Simon de Lusignan from the RCGP’s Research and Surveillance Centre discusses the new RSV vaccination programme, which offers a one-off vaccine to everyone at the age of 75, with an initial catch-up programme between the ages of 75 and 80. He also touches on monoclonal antibodies and antivirals, which are given in secondary care to children who are at high risk of serious complications if they contract RSV.
126 epizódok
MP3•Epizód kép
Manage episode 436655401 series 2631159
A tartalmat a Audioboom and RCGP eLearning Podcast biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Audioboom and RCGP eLearning Podcast vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Sponsored by Pfizer Limited. Pfizer has had no involvement in the editorial component of this educational material. Editorial and content decisions were made solely by the RCGP.
Respiratory syncytial virus (RSV) is an RNA virus which causes respiratory infections; the most significant clinical effects are in infants and people who are elderly and have chronic medical conditions or immunosuppression. In this podcast, Professor Simon de Lusignan from the RCGP’s Research and Surveillance Centre discusses the new RSV vaccination programme, which offers a one-off vaccine to everyone at the age of 75, with an initial catch-up programme between the ages of 75 and 80. He also touches on monoclonal antibodies and antivirals, which are given in secondary care to children who are at high risk of serious complications if they contract RSV.
Respiratory syncytial virus (RSV) is an RNA virus which causes respiratory infections; the most significant clinical effects are in infants and people who are elderly and have chronic medical conditions or immunosuppression. In this podcast, Professor Simon de Lusignan from the RCGP’s Research and Surveillance Centre discusses the new RSV vaccination programme, which offers a one-off vaccine to everyone at the age of 75, with an initial catch-up programme between the ages of 75 and 80. He also touches on monoclonal antibodies and antivirals, which are given in secondary care to children who are at high risk of serious complications if they contract RSV.
126 epizódok
Minden epizód
×Üdvözlünk a Player FM-nél!
A Player FM lejátszó az internetet böngészi a kiváló minőségű podcastok után, hogy ön élvezhesse azokat. Ez a legjobb podcast-alkalmazás, Androidon, iPhone-on és a weben is működik. Jelentkezzen be az feliratkozások szinkronizálásához az eszközök között.